ClinicalTrials.gg
CompletedNCT01023815EVIDENCEUpdated Jul 19, 2016Results posted

Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.

A Phase 3 interventional study of everolimus and cyclosporine in de Novo Kidney Transplant Recipients and Renal Transplantation, sponsored by Novartis. Completed at 28 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-19.

Sponsored by Novartis · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will compare the following immunosuppressive regimens in recipients of kidney transplantation: A) everolimus, cyclosporine and steroids given once-a-day; B) everolimus and cyclosporine given twice a day with steroid withdrawal; C) everolimus, cyclosporine given twice a day and continuous steroids. The purpose of this study is to evaluate regimens A and B in comparison with the control group (group C) for efficacy, using as main endpoint the treatment failure rate, a composite endpoint including death, graft loss, BPAR and lost to follow-up between randomization and Month 12.

02

Conditions studied

  • de Novo Kidney Transplant Recipients
  • Renal Transplantation

Keywords

  • Immunosuppression
  • renal transplantation
  • once-a-day regimen
  • steroid withdrawal
  • drug minimization
  • immunosuppression for prevention of acute rejections
03

In context

Lead sponsor

Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • recipients of 1st or 2nd single kidney transplant
  • donor age >14 years
  • females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at Baseline (Visit 2), and are required to practice an approved method of for the duration of the study and for a period of 2 months following discontinuation of study medication
  • patientswho are willing and able to participate in the study and from whom written has been obtained

Exclusion criteria

Exclusion criteria:

Exclusion criteria at screening (pre-transplantation, Visit 1):

  • recipients of kidney-pancreas transplant, double kidney or any other transplant
  • recipients of a 2nd kidney transplant who lost the 1st for immunological reasons
  • focal segmental glomerulosclerosis (FSGS), primary oxaluria or other diseases (as cause of end stage renal failure - ESRF) at high risk of rapid recurrence or requiring continuous treatment
  • recipients of A-B-O incompatible transplants
  • historical or current peak PRA of >25% (current = 3 months)
  • patients with already existing antibodies against the donor
  • thrombocytopenia ( \<75,000/mm³), of \<1,500/mm³, leucopenia (leucocytes \<2,500/mm³), or \<6 g/dL
  • symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, or to comply with the study requirements, or to give
  • history of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or
  • patients who are positive or surface antigen positive (HbsAg); positive patients receiving interferon and/or ribavirin
  • evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. , ALT or total >3 times UNL)
  • evidence of drug or alcohol abuse
  • (BMI) >35
  • patients who need to be treated with drugs known to strongly interact with CsA and/or everolimus (as detailed in Appendix 2 of the protocol) should be excluded, if according the investigator this interferes with the objectives of the study
  • women of , UNLESS they are using two methods. The two methods can be a double barrier method or a barrier method plus a hormonal method
  • pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/mL)
  • use of other drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
  • history of to any of the study drugs or to drugs of similar chemical classes
  • patients with severe active infections or any other medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)

Additional exclusion criteria post-transplantation (Visit 2):

  • graft not perfused or with thrombosis of the main vessels, according to angioscintigraphy or echocolordoppler within 48 hours after the end of surgical procedure

To avoid any possible influence of the confounding factors on the results of this study additional exclusion criteria at randomization were (Visit 5, Month 3):

  • unsatisfactory renal function ( according Cockcroft and Gault\<40 mL/min)
  • proteinuria ≥0.8 g/24 hrs
  • steroid-resistant, humoral, moderate/severe (BANFF grade ≥II) proven acute rejections
  • multiple (2 or more) biopsy proven or treated acute rejections or acute rejections leading to relevant loss of renal function
  • acute rejection or impairment of renal function (increase of serum creatinine>30%) in the month preceding randomization
  • severe/uncontrollable adverse events with suspected relationship to everolimus (e.g. anemia, oral aphtosis, arthralgia) for the control of which the investigator has planned the withdrawal of everolimus
  • severe infections requiring hospitalization in the two weeks preceding randomization
  • poor compliance to prescribed treatments

    • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Group A -Once-a-day regimen

    Everolimus: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole daily dose of everolimus was taken in the morning, at the same time of the CsA and steroid dosing. At the Rand+1W visit, the everolimus dose was adjusted to reach and maintain everolimus blood levels between 5 and 8 ng/mL until end of Month 12. Cyclosporine: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole cyclosporine daily dose was taken in the morning. The dose was then adjusted to maintain C2 levels between 350 and 700 ng/mL. Prednisone: In patients randomized to Group A before Amendment 1 approval, the dose of prednisone was kept stable at 5 mg/day in the morning.

    Drug: everolimus · Drug: cyclosporine · Drug: Prednison (continuous steroids)

  • Experimental
    Group B - Steroid Withdrawal group

    Everolimus: after randomization the everolimus dose was adjusted, if necessary, to maintain a C0 within 6-10 ng/mL until M12. Cyclosporine:after randomization the cyclosporine dose was adjusted to maintain CsA C2 levels within 300-500 ng/mL until M12. Prednisone: starting from Visit 5 (day 90 ± 28 days), oral prednisone was tapered until complete stop. It was recommended to taper prednisone by 1 mg/week until complete stop in 5 to 6 weeks.

    Drug: everolimus · Drug: cyclosporine · Drug: Prednison (continuous steroids)

  • Active comparator
    Group C - Standard twice-a-day group

    Everolimus: after randomization the everolimus dose was adjusted, if necessary, in order to maintain a C0 within 6-10 ng/mL until M12. Cyclosporine: after randomization the cyclosporine dose was gradually adjusted to reach and maintain C2 blood levels of 200-450 ng/mL between Month 6 and Month 12. Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning.

    Drug: everolimus · Drug: cyclosporine · Drug: Prednison (continuous steroids)

  • Experimental
    Not Randomized Population (NRP)

    NRP defined in whom a renal transplantation was performed, received at least one dose of study drug (everolimus) but who did not qualify for randomization at Visit 5, Day 90. This group was addressed as "not randomized patients" (NRP) and described with respect to baseline characteristics, treatment and outcome variables.

    Drug: everolimus

Interventions

  • Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.

    Also known as: Certican®)

  • Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.

    Also known as: CsA, Sandimmun® Neoral®

  • continuous steroids

06

What researchers measure

Primary outcomes

  1. Treatment Failure Rate

    Occurrence or not of treatment failure in each patient. Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection (a biopsy graded IA, IB, IIA, IIB or III according to Banff '97 grading with 2007 update), graft loss, death or lost to follow-up occurring after randomization (V5) and within M12 (V9).

    Time frame: Between randomization (Month 3) and Month 12

Secondary outcomes

  1. Changes in the Estimated Glomerular Filtration Rate (eGFR) Between Randomization (Month 3) and Month 12

    eGFR by Nankivell, in terms of descriptive statistics and change vs randomization visit - to compare the changes in the estimated GFR (Nankivell) between randomization and Month 12 in the steroid withdrawal group (Group B) to the change observed in the standard twice-a-day group (Group C), for non-inferiority

    Time frame: Month 3 to Month 12

  2. Biopsy Proven Acute Rejection (BPAR) Rate Between Randomization and Month 12

    Occurrence of BPAR (after randomization) between arm B (steroid withdrawal group) and arm c (standard twice-a-day group). BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III according to Banff 1997 grading with 2007 update.

    Time frame: Month 3 to Month 12

  3. Number of Participants With Graft and Patient Survival After Randomization

    Graft Survival, calculated from the date of transplantation to the date of irreversible graft failure signified by return to long-term retransplantation or the date of the last follow-up during the period when the transplant was still functioning or to the date of death. Patient survival, calculated from the date of transplantation to the date of death or the date of the last follow-up.

    Time frame: Month 3 to Month 12

  4. Change in Estimated Creatine Clearance

    At each visit, estimated creatinine clearance was measured in the local laboratory to analyze the evolution of the renal function. The following indirect measures of renal function were computed: estimated creatinine clearance according to Cockcroft and Gault formula and MDRD formula.

    Time frame: M3, M12

  5. Change in Serum Creatinine

    Serum creatinine (a blood measurement) is an important indicator of renal health because it is an easily-measured by-product of muscle metabolism. Measuring serum creatinine is a simple test and it is the most commonly used indicator of renal function.

    Time frame: M3, M12

07

Results

Posted Nov 14, 2013

Participant flow

A total of 332 patients were screened. 330 were pre-randomized, 2 were not. Additionally, 2 pts were not treated which made the safety/ITT population 328. Of the 328, 184 were randomized and 144 were not. Of the 144, 70 dropped before day 90 \& 74 completed the pre-rand period but were not randomized because they were not eligible for randomization.

Pre-randomization Period (Day 1 to 90)
Participant flow — Pre-randomization Period (Day 1 to 90)
MilestonePre-randomized: Not-randomization Patients (NRP)Randomized: Group A - Once-a-day RegimenRandomized: Group B - Steroid Withdrawal GroupRandomized: Group C - Standard Twice-a-day Group
Started328000
Completed184000
Not completed144000
Withdrew: Did not meet inclusion criteria144000
Randomized Period (Day 90 to Month 12)
Participant flow — Randomized Period (Day 90 to Month 12)
MilestonePre-randomized: Not-randomization Patients (NRP)Randomized: Group A - Once-a-day RegimenRandomized: Group B - Steroid Withdrawal GroupRandomized: Group C - Standard Twice-a-day Group
Started0456871
Completed0426068
Not completed0383
Withdrew: Withdrawal by subject0011
Withdrew: Lost to follow-up0110
Withdrew: Administrative problems0162
Withdrew: Graft loss0100

Outcome measures

PrimaryTreatment Failure Rate

Occurrence or not of treatment failure in each patient. Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection (a biopsy graded IA, IB, IIA, IIB or III according to Banff '97 grading with 2007 update), graft loss, death or lost to follow-up occurring after randomization (V5) and within M12 (V9).

Time frame:
Between randomization (Month 3) and Month 12
Reported as:
Number · Participants
Treatment Failure Rate
ParticipantsGroup A - Once-a-day RegimenGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day Group
Treatment Failure Rate3102
SecondaryChanges in the Estimated Glomerular Filtration Rate (eGFR) Between Randomization (Month 3) and Month 12

eGFR by Nankivell, in terms of descriptive statistics and change vs randomization visit - to compare the changes in the estimated GFR (Nankivell) between randomization and Month 12 in the steroid withdrawal group (Group B) to the change observed in the standard twice-a-day group (Group C), for non-inferiority

Time frame:
Month 3 to Month 12
Reported as:
Mean · mL/min
Changes in the Estimated Glomerular Filtration Rate (eGFR) Between Randomization (Month 3) and Month 12
mL/minGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day Group
Changes in the Estimated Glomerular Filtration Rate (eGFR) Between Randomization (Month 3) and Month 12-1.7 ± 9.52.5 ± 10.6
SecondaryBiopsy Proven Acute Rejection (BPAR) Rate Between Randomization and Month 12

Occurrence of BPAR (after randomization) between arm B (steroid withdrawal group) and arm c (standard twice-a-day group). BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III according to Banff 1997 grading with 2007 update.

Time frame:
Month 3 to Month 12
Reported as:
Number · Participants
Biopsy Proven Acute Rejection (BPAR) Rate Between Randomization and Month 12
ParticipantsGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day Group
Biopsy Proven Acute Rejection (BPAR) Rate Between Randomization and Month 1292
SecondaryNumber of Participants With Graft and Patient Survival After Randomization

Graft Survival, calculated from the date of transplantation to the date of irreversible graft failure signified by return to long-term retransplantation or the date of the last follow-up during the period when the transplant was still functioning or to the date of death. Patient survival, calculated from the date of transplantation to the date of death or the date of the last follow-up.

Time frame:
Month 3 to Month 12
Reported as:
Number · Participants
Number of Participants With Graft and Patient Survival After Randomization
ParticipantsGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day Group
Number of Participants With Graft and Patient Survival After Randomization6871
SecondaryChange in Estimated Creatine Clearance

At each visit, estimated creatinine clearance was measured in the local laboratory to analyze the evolution of the renal function. The following indirect measures of renal function were computed: estimated creatinine clearance according to Cockcroft and Gault formula and MDRD formula.

Time frame:
M3, M12
Reported as:
Mean · mL/min
Change in Estimated Creatine Clearance
mL/minGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day Group
Using Cockcroft and Gault model @ month 364.8 ± 21.863.0 ± 20.9
Using Cockcroft and Gault model @ month 1262.3 ± 21.466.9 ± 24.7
Using MDRD-4 formular @ month 357.9 ± 20.058.8 ± 21.8
Using MDRD-4 formular @ month 1253.6 ± 18.961.8 ± 23.1
SecondaryChange in Serum Creatinine

Serum creatinine (a blood measurement) is an important indicator of renal health because it is an easily-measured by-product of muscle metabolism. Measuring serum creatinine is a simple test and it is the most commonly used indicator of renal function.

Time frame:
M3, M12
Reported as:
Mean · mg/dL
Change in Serum Creatinine
mg/dLGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day Group
Serum Creatinine @ month 31.4 ± 0.41.4 ± 0.4
Serum Creatinine @ month 121.5 ± 0.51.4 ± 0.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Not Randomized Population (NRP)—65/144 (45.1%)108/144 (75%)
Group A - Once-a-day Regimen—18/45 (40%)35/45 (77.8%)
Group B - Steroid Withdrawal Group—24/68 (35.3%)56/68 (82.4%)
Group C - Standard Twice-a-day Group—25/71 (35.2%)57/71 (80.3%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventNot Randomized Population (NRP)Group A - Once-a-day RegimenGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day Group
Transplant rejectionImmune system disorders11/1440/456/682/71
Urinary tract infectionInfections and infestations0/1442/456/680/71
Renal impairmentRenal and urinary disorders5/1441/454/686/71
Blood creatinine increasedInvestigations5/1442/455/683/71
LymphoceleVascular disorders2/1443/452/681/71
HyperpyrexiaGeneral disorders0/1440/454/680/71
Graft lossInjury, poisoning and procedural complications7/1440/450/680/71
PyrexiaGeneral disorders2/1442/450/680/71
Kidney transplant rejectionImmune system disorders2/1442/451/681/71
Toxicity to various agentsInjury, poisoning and procedural complications4/1440/453/681/71
Most frequent other events
Showing 10 of 31
Most frequent other events
EventNot Randomized Population (NRP)Group A - Once-a-day RegimenGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day Group
AnaemiaBlood and lymphatic system disorders53/14410/4523/6813/71
HyperlipidaemiaMetabolism and nutrition disorders16/14412/4520/6818/71
Oedema peripheralGeneral disorders7/1446/4516/689/71
Urinary tract infectionInfections and infestations25/1447/4514/6816/71
HypertensionVascular disorders25/1448/4511/6814/71
Complications of transplanted kidneyInjury, poisoning and procedural complications22/1447/456/688/71
Blood creatinine increasedInvestigations6/1446/455/683/71
HypokalaemiaMetabolism and nutrition disorders18/1446/457/686/71
DiarrhoeaGastrointestinal disorders7/1443/458/681/71
HypocalcaemiaMetabolism and nutrition disorders15/1445/457/683/71

Baseline characteristics

Safety Population: The Safety Population (SAF population) includes all patients who signed an informed consent, performed renal transplantation and received at least one dose of study drug (everolimus).

Age, Continuous
Age, Continuous(years)Not Randomized Population (NRP)Group A - Once-a-day RegimenGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day GroupTotal
Mean52.9 ± 11.546.6 ± 13.748.5 ± 11.649.2 ± 13.050.3 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Not Randomized Population (NRP)Group A - Once-a-day RegimenGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day GroupTotal
Female56152220113
Male88304651215
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Not Randomized Population (NRP)Group A - Once-a-day RegimenGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day GroupTotal
Caucasian139446867318
Black30014
Oriental11002
Other10034
Smoking Status
Smoking Status(Participants)Not Randomized Population (NRP)Group A - Once-a-day RegimenGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day GroupTotal
No119415856274
Yes1622222
Missing9281332
BMI
BMI(kg/m^2)Not Randomized Population (NRP)Group A - Once-a-day RegimenGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day GroupTotal
Mean24.6 ± 3.424.9 ± 3.624.1 ± 3.324.2 ± 3.624.4 ± 3.4
Female reproductive status
Female reproductive status(Participants)Not Randomized Population (NRP)Group A - Once-a-day RegimenGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day GroupTotal
Childbearing potential with contraceptive protecti11812435
Surgically sterilised20204
Postmenopausal43781674
Result of HCG pregnancy screen - Negative
Result of HCG pregnancy screen - Negative(Participants)Not Randomized Population (NRP)Group A - Once-a-day RegimenGroup B - Steroid Withdrawal GroupGroup C - Standard Twice-a-day GroupTotal
Negative10612432
Missing469101681
08

Study locations

28 sites
  • Novartis Investigative Site
    Ancona, 60100, Italy
  • Novartis Investigative Site
    Bologna, Italy
  • Novartis Investigative Site
    Brescia, Italy
  • Novartis Investigative Site
    Cagliari, Italy
  • Novartis Investigative Site
    Catania, Italy
  • Novartis Investigative Site
    Coppito, Italy
  • Novartis Investigative Site
    Firenze, Italy
  • Novartis Investigative Site
    Genova, 16132, Italy
  • Novartis Investigative Site
    Milano, 20122, Italy
  • Novartis Investigative Site
    Modena, 41100, Italy
  • Novartis Investigative Site
    Napoli, Italy
  • Novartis Investigative Site
    Novara, 28100, Italy
  • Novartis Investigative Site
    Padova, Italy
  • Novartis Investigative Site
    Palermo, Italy
  • Novartis Investigative Site
    Parma, Italy
  • Novartis Investigative Site
    Perugia, 06070, Italy
  • Novarits Investigative Site
    Pisa, Italy
  • Novartis Investigative Site
    Roma, Italy
  • Novartis Investigative Site
    Rome, Italy
  • Novartis Investigative Site
    Salerno, Italy
  • Novartis Investigative Site
    Sassari, 07100, Italy
  • Novartis Investigative Site
    Siena, 53100, Italy
  • Novartis Investigative Site
    Torino, 10126, Italy
  • Novartis Investigative Site
    Treviso, Italy
  • Novartis InvestigativeSite
    Udine, Italy
  • Novartis Investigative Site
    Varese, Italy
  • Novartis Investigative Site
    Verona, Italy
  • Novartis Investigative Site
    Vicenza, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2009
First posted
Dec 2, 2009
Start
Apr 2009
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Nov 14, 2013
Last update
Jul 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01023815
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Dec 2, 2009
Start date
Apr 2009
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Nov 14, 2013
Last update
Jul 19, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion